...
首页> 外文期刊>Research and practice in thrombosis and haemostasis. >Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
【24h】

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

机译:在A或B血友病患者中进行和解释个体药代动力学特征:基本原理和一般注意事项

获取原文

摘要

Objectives In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited samples in persons with hemophilia with the goal to optimize prophylaxis with clotting factor concentrates. This paper, intended for clinicians, aims to describe how to interpret and apply PK properties obtained in persons with hemophilia. Methods The members of the Working Party on population PK (PopPK) of the ISTH SSC Subcommittee on Factor VIII and IX and rare bleeding disorders, together with additional hemophilia and PK experts, completed a survey and ranking exercise whereby key areas of interest in the field were identified. The group had regular web conferences to refine the manuscript’s scope and structure, taking into account comments from the external feedback to the earlier document. Results Many clinical decisions in hemophilia are based on some form of explicit or implicit PK assessment. Individual patient PK profiles can be analyzed through traditional or PopPK methods, with the latter providing the advantage of fewer samples needing to be collected on any prophylaxis regimen, and without the need the for a washout period. The most useful presentation of PK results for clinical decision making are a curve of the factor activity level over time, the time to achieve a certain activity level, or related parameters like half‐life or exposure (AUC). Software platforms have been developed to deliver this information to clinicians at the point of care. Key characteristics of studies measuring average PK parameters were reviewed, outlining what makes a credible head‐to‐head comparison among different concentrates. Large data collections of PK and treatment outcomes currently ongoing will advance care in the future. Conclusions Traditionally used to compare different concentrates, PK can support tailoring of hemophilia treatment by individual profiling, which is greatly simplified by adopting a PopPK/Bayesian method and limited sampling protocol.
机译:目标在另一份文件中,我们为血友病患者使用有限的样本进行个体药代动力学(PK)研究提供了具体指导,目的是优化凝血因子浓缩物的预防。本文面向临床医生,旨在描述如何解释和应用血友病患者获得的PK特性。方法ISTH SSC VIII和IX因子及罕见出血性疾病小组委员会的PK人群工作小组成员与其他血友病和PK专家一起完成了一项调查和排名练习,从而对该领域的关键领域感兴趣被确定。该小组定期召开网络会议,以考虑到外部反馈对早期文档的评论,以完善手稿的范围和结构。结果血友病的许多临床决策都是基于某种形式的显式或隐式PK评估。可以通过传统方法或PopPK方法分析单个患者的PK曲线,后者具有以下优点:在任何预防方案下都需要收集较少的样品,而无需进行清洗。对于临床决策而言,最有用的PK结果表述是因子活性水平随时间变化,达到一定活性水平的时间或相关参数(如半衰期或暴露(AUC))的曲线。已经开发了软件平台,以便在护理点将这些信息传递给临床医生。综述了测量平均PK参数的研究的关键特征,概述了在不同精矿之间进行可靠的头对头比较的原因。当前正在进行的有关PK和治疗结果的大数据收集将在未来推动医疗服务。结论PK通常用于比较不同的浓缩物,可以通过个人分析来支持血友病治疗的定制,采用PopPK /贝叶斯方法和有限的采样方案可以大大简化血友病的治疗。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号